Progesterone Is Associated With Increased Vasohibin‐2 Expression, Tubulin Detyrosination, and Paclitaxel Sensitivity in PR ‐Negative Ovarian Cancer Cells
Cancer Reports · 2026
DOI: 10.1002/cnr2.70681 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2026. Verfasst von Takahiro Koyanagi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan. Hauptthemen laut MEDLINE: Paclitaxel, Ovarian Neoplasms, Tubulin, Progesterone. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science, and Technology of Japan.
Abstract (Originalsprache)
Background
Progesterone induces rapid cellular responses in progesterone receptor (PR)‐negative ovarian cancer cells that are consistent with non‐genomic progesterone signaling. Vasohibin‐2 (VASH2), originally identified as a pro‐angiogenic factor, has recently been recognized as a tubulin carboxypeptidase involved in microtubule regulation.
Aims
This study investigated the association of progesterone treatment with VASH2‐related molecular changes and paclitaxel sensitivity in ovarian cancer cells.
Methods
Two PR‐negative ovarian cancer cell lines expressing membrane progesterone receptors (mPRs) were treated with progesterone. VASH2 mRNA expression was evaluated by RT‐qPCR, whereas detyrosinated tubulin and cyclin B1 expression were assessed by western blotting. Paclitaxel and gemcitabine sensitivities were determined using WST‐1 cell viability assays.
Results
Progesterone treatment was associated with increased VASH2 mRNA expression, enhanced tubulin detyrosination, cyclin B1 accumulation, and significantly reduced paclitaxel IC 50 values in both cell lines. In contrast, progesterone had no significant effect on gemcitabine sensitivity.
Conclusion
Progesterone treatment was associated with increased VASH2 expression, enhanced tubulin detyrosination, and increased paclitaxel sensitivity in PR‐negative ovarian cancer cells. These findings provide in vitro evidence supporting further mechanistic and preclinical investigation of progesterone as a potential adjunct to paclitaxel therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, School of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
- Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
ORCID-Profile: Takahiro Koyanagi, Yasushi Saga, Yoshifumi Takahashi, Yuji Takei, Hiroyuki Fujiwara
Förderung
- Ministry of Education, Culture, Sports, Science, and Technology of Japan
Zitieren
APA
Koyanagi, T., Saga, Y., Takahashi, Y., Tamura, K., Suizu, E., Yamamoto, K., Taneichi, A., Takei, Y., Mizukami, H., & Fujiwara, H. (2026). Progesterone Is Associated With Increased Vasohibin‐2 Expression, Tubulin Detyrosination, and Paclitaxel Sensitivity in PR ‐Negative Ovarian Cancer Cells. Cancer Reports. https://doi.org/10.1002/cnr2.70681
Vancouver
Koyanagi T, Saga Y, Takahashi Y, Tamura K, Suizu E, Yamamoto K, et al. Progesterone Is Associated With Increased Vasohibin‐2 Expression, Tubulin Detyrosination, and Paclitaxel Sensitivity in PR ‐Negative Ovarian Cancer Cells. Cancer Reports. 2026. doi:10.1002/cnr2.70681
BibTeX
@article{Koyanagi2026,
author = {Koyanagi, Takahiro and Saga, Yasushi and Takahashi, Yoshifumi and Tamura, Kohei and Suizu, Eri and Yamamoto, Kazuki and Taneichi, Akiyo and Takei, Yuji and Mizukami, Hiroaki and Fujiwara, Hiroyuki},
title = {Progesterone Is Associated With Increased Vasohibin‐2 Expression, Tubulin Detyrosination, and Paclitaxel Sensitivity in PR ‐Negative Ovarian Cancer Cells},
journal = {Cancer Reports},
year = {2026},
doi = {10.1002/cnr2.70681}
}
EUVIMED